Pfizer Earnings Estimate
PFE Stock | USD 27.75 0.03 0.11% |
Pfizer |
Pfizer Earnings Estimation Breakdown
The calculation of Pfizer's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pfizer is estimated to be 0.54 with the future projection ranging from a low of 0.34 to a high of 0.76. Please be aware that this consensus of annual earnings estimates for Pfizer Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.34 Lowest | Expected EPS | 0.76 Highest |
Pfizer Earnings Projection Consensus
Suppose the current estimates of Pfizer's value are higher than the current market price of the Pfizer stock. In this case, investors may conclude that Pfizer is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pfizer's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2024 | Current EPS (TTM) | |
22 | 67.46% | 0.1 | 0.54 | 0.37 |
Pfizer Earnings History
Earnings estimate consensus by Pfizer Inc analysts from Wall Street is used by the market to judge Pfizer's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Pfizer's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Pfizer Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pfizer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pfizer Earnings per Share Projection vs Actual
Actual Earning per Share of Pfizer refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pfizer Inc predict the company's earnings will be in the future. The higher the earnings per share of Pfizer, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Pfizer Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Pfizer, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pfizer should always be considered in relation to other companies to make a more educated investment decision.Pfizer Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Pfizer's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-01-30 | 2023-12-31 | -0.22 | 0.1 | 0.32 | 145 | ||
2023-10-31 | 2023-09-30 | -0.34 | -0.17 | 0.17 | 50 | ||
2023-08-01 | 2023-06-30 | 0.57 | 0.67 | 0.1 | 17 | ||
2023-05-02 | 2023-03-31 | 0.98 | 1.23 | 0.25 | 25 | ||
2023-01-31 | 2022-12-31 | 1.05 | 1.14 | 0.09 | 8 | ||
2022-11-01 | 2022-09-30 | 1.39 | 1.78 | 0.39 | 28 | ||
2022-07-28 | 2022-06-30 | 1.78 | 2.04 | 0.26 | 14 | ||
2022-05-03 | 2022-03-31 | 1.47 | 1.67 | 0.2 | 13 | ||
2022-02-08 | 2021-12-31 | 0.87 | 1.08 | 0.21 | 24 | ||
2021-11-02 | 2021-09-30 | 1.09 | 1.34 | 0.25 | 22 | ||
2021-07-28 | 2021-06-30 | 0.97 | 1.07 | 0.1 | 10 | ||
2021-05-04 | 2021-03-31 | 0.77 | 0.93 | 0.16 | 20 | ||
2021-02-02 | 2020-12-31 | 0.48 | 0.42 | -0.06 | 12 | ||
2020-10-27 | 2020-09-30 | 0.71 | 0.72 | 0.01 | 1 | ||
2020-07-28 | 2020-06-30 | 0.66 | 0.78 | 0.12 | 18 | ||
2020-04-28 | 2020-03-31 | 0.73 | 0.8 | 0.07 | 9 | ||
2020-01-28 | 2019-12-31 | 0.58 | 0.55 | -0.03 | 5 | ||
2019-10-29 | 2019-09-30 | 0.62 | 0.75 | 0.13 | 20 | ||
2019-07-29 | 2019-06-30 | 0.75 | 0.8 | 0.05 | 6 | ||
2019-04-30 | 2019-03-31 | 0.75 | 0.85 | 0.1 | 13 | ||
2019-01-29 | 2018-12-31 | 0.63 | 0.64 | 0.01 | 1 | ||
2018-10-30 | 2018-09-30 | 0.75 | 0.78 | 0.03 | 4 | ||
2018-07-31 | 2018-06-30 | 0.74 | 0.81 | 0.07 | 9 | ||
2018-05-01 | 2018-03-31 | 0.74 | 0.77 | 0.03 | 4 | ||
2018-01-30 | 2017-12-31 | 0.56 | 0.62 | 0.06 | 10 | ||
2017-10-31 | 2017-09-30 | 0.64 | 0.67 | 0.03 | 4 | ||
2017-08-01 | 2017-06-30 | 0.66 | 0.67 | 0.01 | 1 | ||
2017-05-02 | 2017-03-31 | 0.67 | 0.69 | 0.02 | 2 | ||
2017-01-31 | 2016-12-31 | 0.5 | 0.47 | -0.03 | 6 | ||
2016-11-01 | 2016-09-30 | 0.62 | 0.61 | -0.01 | 1 | ||
2016-08-02 | 2016-06-30 | 0.62 | 0.64 | 0.02 | 3 | ||
2016-05-03 | 2016-03-31 | 0.55 | 0.67 | 0.12 | 21 | ||
2016-02-02 | 2015-12-31 | 0.52 | 0.53 | 0.01 | 1 | ||
2015-10-27 | 2015-09-30 | 0.51 | 0.6 | 0.09 | 17 | ||
2015-07-28 | 2015-06-30 | 0.52 | 0.56 | 0.04 | 7 | ||
2015-04-28 | 2015-03-31 | 0.49 | 0.51 | 0.02 | 4 | ||
2015-01-27 | 2014-12-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2014-10-28 | 2014-09-30 | 0.55 | 0.57 | 0.02 | 3 | ||
2014-07-29 | 2014-06-30 | 0.57 | 0.58 | 0.01 | 1 | ||
2014-05-05 | 2014-03-31 | 0.55 | 0.57 | 0.02 | 3 | ||
2014-01-28 | 2013-12-31 | 0.52 | 0.56 | 0.04 | 7 | ||
2013-10-29 | 2013-09-30 | 0.56 | 0.58 | 0.02 | 3 | ||
2013-07-30 | 2013-06-30 | 0.55 | 0.56 | 0.01 | 1 | ||
2013-04-30 | 2013-03-31 | 0.55 | 0.54 | -0.01 | 1 | ||
2013-01-29 | 2012-12-31 | 0.44 | 0.47 | 0.03 | 6 | ||
2012-11-01 | 2012-09-30 | 0.53 | 0.53 | 0.0 | 0 | ||
2012-07-31 | 2012-06-30 | 0.54 | 0.62 | 0.08 | 14 | ||
2012-05-01 | 2012-03-31 | 0.56 | 0.58 | 0.02 | 3 | ||
2012-01-31 | 2011-12-31 | 0.47 | 0.5 | 0.03 | 6 | ||
2011-11-01 | 2011-09-30 | 0.56 | 0.62 | 0.06 | 10 | ||
2011-08-02 | 2011-06-30 | 0.59 | 0.6 | 0.01 | 1 | ||
2011-05-03 | 2011-03-31 | 0.59 | 0.6 | 0.01 | 1 | ||
2011-02-01 | 2010-12-31 | 0.46 | 0.47 | 0.01 | 2 | ||
2010-11-02 | 2010-09-30 | 0.51 | 0.54 | 0.03 | 5 | ||
2010-08-03 | 2010-06-30 | 0.52 | 0.62 | 0.1 | 19 | ||
2010-05-04 | 2010-03-31 | 0.53 | 0.6 | 0.07 | 13 | ||
2010-02-03 | 2009-12-31 | 0.5 | 0.49 | -0.01 | 2 | ||
2009-10-20 | 2009-09-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2009-07-22 | 2009-06-30 | 0.47 | 0.48 | 0.01 | 2 | ||
2009-04-28 | 2009-03-31 | 0.49 | 0.54 | 0.05 | 10 | ||
2009-01-26 | 2008-12-31 | 0.59 | 0.65 | 0.06 | 10 | ||
2008-10-21 | 2008-09-30 | 0.6 | 0.62 | 0.02 | 3 | ||
2008-07-23 | 2008-06-30 | 0.54 | 0.55 | 0.01 | 1 | ||
2008-04-17 | 2008-03-31 | 0.66 | 0.61 | -0.05 | 7 | ||
2008-01-23 | 2007-12-31 | 0.47 | 0.52 | 0.05 | 10 | ||
2007-10-18 | 2007-09-30 | 0.53 | 0.58 | 0.05 | 9 | ||
2007-07-18 | 2007-06-30 | 0.5 | 0.42 | -0.08 | 16 | ||
2007-04-20 | 2007-03-31 | 0.57 | 0.68 | 0.11 | 19 | ||
2007-01-22 | 2006-12-31 | 0.42 | 0.43 | 0.01 | 2 | ||
2006-10-19 | 2006-09-30 | 0.45 | 0.54 | 0.09 | 20 | ||
2006-07-20 | 2006-06-30 | 0.48 | 0.5 | 0.02 | 4 | ||
2006-04-19 | 2006-03-31 | 0.53 | 0.61 | 0.08 | 15 | ||
2006-01-19 | 2005-12-31 | 0.42 | 0.51 | 0.09 | 21 | ||
2005-10-20 | 2005-09-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2005-07-20 | 2005-06-30 | 0.44 | 0.46 | 0.02 | 4 | ||
2005-04-19 | 2005-03-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2005-01-19 | 2004-12-31 | 0.59 | 0.58 | -0.01 | 1 | ||
2004-10-20 | 2004-09-30 | 0.54 | 0.55 | 0.01 | 1 | ||
2004-07-21 | 2004-06-30 | 0.47 | 0.47 | 0.0 | 0 | ||
2004-04-20 | 2004-03-31 | 0.51 | 0.52 | 0.01 | 1 | ||
2004-01-22 | 2003-12-31 | 0.51 | 0.53 | 0.02 | 3 | ||
2003-10-22 | 2003-09-30 | 0.44 | 0.47 | 0.03 | 6 | ||
2003-07-25 | 2003-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2003-04-22 | 2003-03-31 | 0.44 | 0.45 | 0.01 | 2 | ||
2003-01-22 | 2002-12-31 | 0.47 | 0.48 | 0.01 | 2 | ||
2002-10-16 | 2002-09-30 | 0.39 | 0.39 | 0.0 | 0 | ||
2002-07-15 | 2002-06-30 | 0.32 | 0.33 | 0.01 | 3 | ||
2002-04-17 | 2002-03-31 | 0.39 | 0.39 | 0.0 | 0 | ||
2002-01-23 | 2001-12-31 | 0.34 | 0.34 | 0.0 | 0 | ||
2001-10-17 | 2001-09-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2001-07-17 | 2001-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2001-04-18 | 2001-03-31 | 0.31 | 0.33 | 0.02 | 6 | ||
2001-01-24 | 2000-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2000-10-24 | 2000-09-30 | 0.26 | 0.27 | 0.01 | 3 | ||
2000-07-24 | 2000-06-30 | 0.22 | 0.23 | 0.01 | 4 | ||
2000-04-18 | 2000-03-31 | 0.25 | 0.28 | 0.03 | 12 | ||
2000-01-18 | 1999-12-31 | 0.23 | 0.25 | 0.02 | 8 | ||
1999-10-19 | 1999-09-30 | 0.21 | 0.23 | 0.02 | 9 | ||
1999-07-19 | 1999-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
1999-04-15 | 1999-03-31 | 0.21 | 0.21 | 0.0 | 0 | ||
1999-01-19 | 1998-12-31 | 0.17 | 0.18 | 0.01 | 5 | ||
1998-10-13 | 1998-09-30 | 0.19 | 0.17 | -0.02 | 10 | ||
1998-07-09 | 1998-06-30 | 0.15 | 0.17 | 0.02 | 13 | ||
1998-04-14 | 1998-03-31 | 0.18 | 0.18 | 0.0 | 0 | ||
1998-01-20 | 1997-12-31 | 0.14 | 0.14 | 0.0 | 0 | ||
1997-10-14 | 1997-09-30 | 0.15 | 0.15 | 0.0 | 0 | ||
1997-07-15 | 1997-06-30 | 0.12 | 0.12 | 0.0 | 0 | ||
1997-04-15 | 1997-03-31 | 0.16 | 0.16 | 0.0 | 0 | ||
1997-01-16 | 1996-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-10-14 | 1996-09-30 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-07-17 | 1996-06-30 | 0.1 | 0.1 | 0.0 | 0 | ||
1996-04-16 | 1996-03-31 | 0.13 | 0.14 | 0.01 | 7 | ||
1996-01-17 | 1995-12-31 | 0.11 | 0.11 | 0.0 | 0 | ||
1995-10-15 | 1995-09-30 | 0.11 | 0.11 | 0.0 | 0 |
About Pfizer Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Pfizer earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Pfizer estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Pfizer fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.Last Reported | Projected for 2024 | ||
Retained Earnings | 118.4 B | 124.3 B | |
Retained Earnings Total Equity | 118.4 B | 87 B | |
Price Earnings Ratio | 76.67 | 80.50 | |
Price Earnings To Growth Ratio | (0.82) | (0.78) |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.